Last reviewed · How we verify
Rheumatic IMmune-Related Adverse Events in Patients Treated With Immune Check Point Inhibitors (RIMRA)
RIMRA is a prospective, longitudinal, observational study including patients with de novo symptoms of rheumatic disease or a flare of established rheumatic disease after treatment with an immune check point inhibitor. The aim of the study is to describe the clinical presentation, disease course and outcome of rheumatic irAEs in patients treated with immune check point inhibitors.
Details
| Lead sponsor | Diakonhjemmet Hospital |
|---|---|
| Status | COMPLETED |
| Enrolment | 69 |
| Start date | Mon Mar 05 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Immune-related Adverse Event
Interventions
- Antiinflammatory/DMARDs
Countries
Norway